The frequency of acute leukemia in children with constitutional DNA repair defects implicates defective DNA repair in leukemogenesis. Whether sporadic cases of AML also arise from an inherited genetic predisposition remains to be determined. Prior studies have reported microsatellite instability (MSI) in AML, particularly secondary and relapsed AML. These studies included small numbers of cases in which key features such as cytogenetic abnormalities were not reported. To determine whether defective DNA mismatch repair, reflected by MSI, is a defining feature of adult myeloid leukemogenesis, we retrospectively studied 132 AML cases including 28 de novo, 62 secondary, 22 relapsed/refractory, 15 cases of paired diagnosis/relapse. 110 patients were elderly (55+ years). The cases included a range of cytogenetic abnormalities. MSI was assessed at three loci (BAT 25, BAT 26, BAT 40) in DNA isolated from sorted leukemic blasts and paired T cell controls. Fluoresceinated PCR products were analyzed using an automated capillary electrophoresis system. Of the 132 AML cases, no single case demonstrated MSI. Our studies indicate that MSI, and defective DNA mismatch repair, is not a defining feature of the majority of adult patients with AML. Furthermore, our data does not support the hypothesis that MSI could be acquired during the progression of AML from diagnosis to relapse, as a consequence of therapeutic exposure. Leukemia (2000) 14, 1044-1051.
Introduction
The etiology of acute leukemia is complex and both host genetic and environmental factors have been implicated. The increased frequency of acute leukemia and myelodysplasia (MDS) in children affected with Fanconi anemia's, Bloom's syndrome or ataxia telangiectasia, supports the hypothesis that an underlying genetic predisposition, particularly DNA repair deficits, may predispose to leukemogenesis. Further evidence for a genetic predisposition to AML and MDS comes from the recent mapping of two chromosomal loci (16q21-23 and 21q22) that predispose families to the development of AML and MDS. 1, 2 Whether more common sporadic cases of MDS and AML also arise from a complex genetic predisposition remains to be determined. It is possible to speculate that many forms of AML in children and adults may arise from a complex inherited predisposition, such as deficits in DNA repair or genomic stability, coupled to environmental exposures.
Recent studies have implicated a particular form of DNA repair, DNA mismatch repair, in leukemogenesis. Mismatched bases in DNA may arise from errors during DNA replication, from chemical modifications of DNA, or strand exchange during homologous recombination. The repair of such mispaired bases is essential for reducing the frequency of mutations and maintaining the integrity of the genome. A direct relationship between genomic instability secondary to mutations of the DNA mismatch repair genes, and predisposition to colon carcinoma was established in hereditary nonpolyposis colon cancer (HNPCC). [3] [4] [5] [6] [7] In these studies, genomic instability was demonstrated by analyzing the length of microsatellite loci. Microsatellites are short (1-4 nucleotide) repeated sequences of DNA found throughout the human genome, usually located within introns. These sequences are not transcribed or translated and are a source of redundancy in the genome which are unique in length between, but held constant within, each individual. During DNA replication, microsatellite regions are particularly prone to error compared to other regions of DNA, so that alterations in mismatch repair genes are reflected as either contractions or expansions (termed microsatellite instability or MSI) of these regions.
A search for evidence of mismatch repair deficiency as reflected by MSI has been the object of many studies involving human lymphomas and leukemias. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Using a wide variety of methods to detect MSI, various biological subtypes of AML have been studied several times. Cytogenetic findings and disease status were not always controlled in these prior studies which have totalled: 82 cases of unselected AML with MSI rate of 3-10%, 10, 16, 17 15, 18, 19 Therapy-induced AML (t-AML) exhibited a low rate of MSI in one study (14% in 14 cases) but an extremely high rate (94% in 16 cases) in another. 20, 21 This latter study implied that mismatch repair defects may be an etiologic factor in leukemogenesis for this particular subset of AML. Most of these studies have analyzed low numbers of patients, or used a variety of primers to different microsatellite loci and older radioactive gel-based methods, which make it difficult to distinguish loss of heterozygosity from MSI. For our MSI study, we analyzed the largest series of patients to date and have included their cytogenetic information. We chose the BAT loci (BAT25, BAT26, and BAT40) which are mononucleotide repeats that were rated among the most sensitive loci for detecting MSI in a recent study of colon carcinoma, 7 and which have been successfully used in a study of MSI in therapy-induced AML (t-AML). 21 Finally, we have employed a new sensitive fluorescent technology, which makes interpretation of MSI relatively straightforward and easy.
A total of 132 cases were selected from three Southwest Oncology Group studies that included patients with previously untreated secondary AML. Study 9031 was open from November 1991 until February 1994, to patients of age Ͼ55 years with previously untreated non-M3 secondary or de novo AML. 22 Study 8326 (May 1985 until May 1992) included patients of any age with previously untreated secondary AML or with relapsed or refractory AML. Study 9126 (March 1993 until March 1998) included patients of age 18-70 years with previously untreated secondary AML or RAEB-t, or with relapsed or refractory AML. In all of these studies, secondary AML was defined on the basis of a clinical history of prior myelodysplasia or exposure to leukemogenic chemotherapy or radiotherapy. Selection of patients for this study was limited to patients with cryopreserved bone marrow or peripheral blood available from the Southwest Oncology Group Myeloid Leukemia Repository. Submission of pretreatment marrow or blood specimens to the Repository was mandatory for all patients on studies 9031 and 9126, and for patients registered on study 8326 after July 1989, however, patients whose supply of cryopreserved cells had been exhausted for other studies or whose blasts did not express CD34 were necessarily excluded from this study.
Initially the aim of the present study was to compare the prevalence of MSI between patients with secondary and de novo AML, and patients were therefore selected from study 9031, maintaining blindness to disease onset. However the aim was revised somewhat when no MSI-positive cases were detected in the first 40 patient samples studied. To increase the precision of the estimated prevalence of MSI in cases with secondary AML, case selection was expanded to studies 8326 and 9126. Approximately equal numbers of randomly selected cases with relapsed/refractory AML were also included from these studies in order to maintain blindness to disease onset. After more than 100 cases were studied and none with MSI were found, an additional set of cases with secondary AML, relapsed AML, or AML with cytogenetic abnormalities of chromosomes 5 and/or 7 were selected without blinding from studies 8326 and 9031. Because of the way these patients were selected, the distribution of disease status is arbitrary and not representative of any defined population of AML patients. However estimation of the prevalence of MSI within each disease status category is valid.
Cytogenetic analysis
Cytogenetic studies on pretreatment bone marrow or unstimulated blood samples were performed using standard G-banding with Trypsin-Giemsa or Trypsin-Wright's staining in SWOG approved cytogenetics laboratories. Karyotypes were interpreted using International System for Cytogenetic nomenclature (ISCN) criteria. Karyotypic abnormalities were grouped in favorable, intermediate, or unfavorable categories based on published literature for correlation with clinical outcomes as described previously for SWOG protocols. 23 The favorable cytogenetics group consisted of those cases characterized by t(8;21), inv (16) 
Cell separation
Two methods of cell separation were employed sequentially. First, using the Miltenyi VarioMACS magnetic cell sorting separator (Biotec, Sunnyvale, CA, USA), CD34 antibody-coated magnetic beads were used to enrich the CD34 + blast population. The CD34-negative fraction then underwent flow cytometric cell sorting to obtain a pure T cell population. Sorting was performed on the Epics Elite cell sorting system (Coulter, Miami, FL, USA), using low forward vs low side scatter as well as bright CD45 expression to identify the T lymphocytes. This final sorted population was used as the normal control T cell DNA for MSI analysis. An example histogram showing greater than 95% purity of the T cell population is shown in Figure 1 .
PCR
DNA was isolated from the cells using Puregene kits (Gentra Systems, Minneapolis, MN, USA) according to the manufacturer's directions. PCR was performed using three different sets of primers for the BAT loci. We used BAT25 (intron of the ckit oncogene), BAT26 (intron 5 of hMSH2), and BAT40 (intron of the 3-hydroxysteroid dehydrogenase gene). 7, 24 One primer per loci was 5Ј end labeled with a fluorescent tag that emits light of a different wavelength as follows: one BAT25 primer was labeled with 6-FAM (6-carboxyfluorescein), one BAT26 primer was labeled with HEX (4,7,2Ј,4Ј,5Ј,7Ј-hexachloro-6-carboxyfluorescein), one BAT 40 primer was labeled with TET (4,7,2Ј,7Ј-tetrachloro-6-carboxyfluorescein). These primers are incorporated during the PCR reaction to create a fluorescently labeled product. The PCR mixture consisted of 50-100 ng of DNA, 0.5 units of Taq polymerase (Perkin-Elmer, Foster City, CA, USA), 2.5 pm of primer in the Perkin-Elmer PCR buffer. Thirty cycles of PCR were performed on the GeneAmp PCR system (Perkin-Elmer) consisting of an initial 3 min denaturation at 94°C followed by 30 cycles including denaturation (94°C for 1 min), followed by annealing (58°C for 30 s), and synthesis (72°C for 1 min). A final 6 min at 72°C to allow further synthesis was followed by a hold temperature of 45°C. An aliquot of the PCR products (0.5 l for BAT25 and BAT40 products and 1.0 l from BAT26 products) from each of the three primer sets were combined into one tube, denatured with formamide and temperature (3 min at 95°C) then analyzed as below. A size standard (0.5 l of TAMARA-520) was also added.
Product analysis
DNA fragment length analysis was performed on the ABIPrism 310 Genetic Analyzer laser-induced fluorescence capillary electrophoresis system (Perkin-Elmer). In this system, fluorescent dye-labeled DNA fragments electrophoresed through a polymer so that DNA fragments were separated according to size. The fluorescent dyes attached to the fragments were excited to emit light at a specific wavelength for each dye. All three colors of fluorescent emissions could be detected simultaneously using a CCD camera. A printout of product lengths, color coded by type of fluorescence, was generated Example dot blot generated by FacScan analysis before and after the CD34 + cells have been selected with magnetic beads (see text for details). The initial population is shown in the left panel. After CD34 separation, the population is greatly enriched for presumed T cells (bright CD45 vs low forward scatter) as demonstrated in the middle panel. This gated specimen was then sorted on an Epic Elite system using the CD3 antibody to further purify the T cell population. Final purity of the CD3 population used to isolate the normal control DNA for each patient was greater than 95% (right panel). Y axis = CD45; X axis = forward scatter. on one graph which was then compared to the product length pattern of the control T lymphocytes from the same patient to determine if microsatellite expansion or contraction had occurred.
Statistical analysis
Exact confidence limits for the prevalence of MSI were calculated using Bonferroni adjustment to assure an overall confidence level of at least 95% when subsets of cases were analyzed separately.
Results
Because the literature suggested that MSI was more frequent in secondary (following chemotherapy, radiotherapy, or myelodysplasia), elderly, or cytogenetically complex AML, we selected a group of patients from our treatment trials, heavily weighted towards the aforementioned groups. The 132 patients in this study included 80, 27 and 25 patients from studies 9031, 8326 and 9126, respectively. The 132 patients included 59 previously untreated patients with clinical histories of secondary AML. Three additional previously untreated patients with abnormalities on chromosomes 5 and/or 7 were included among the secondary AML cases for this analysis. As a result, 62 cases were classified as untreated secondary AML, 48 untreated de novo AML, and 22 relapsed or refractory AML. There were 110 patients over the age of 55 years. Patient characteristics are summarized in Table 1 . A variety of FAB diagnoses were included with a predominance of M1, M2 and M4. Cytogenetic findings were used to select cases of poor prognosis and probable secondary AML to weight this study for these sorts of cases. Cytogenetic status by central review indicated that a majority of patients were in the intermediate prognosis category followed by poor prognosis then favorable prognosis (as described under Methods). It should be noted that the 132 patients in this study were atypical in some respects. They were compared to 410 patients in the same disease status strata from the same three clinical trials who were not included in this study (due to unavailability of cryopreserved cells); the comparison patients from study 8326 were also limited to those registered after July 1989. As shown in Table 1 , the patients included had much higher median WBC and peripheral blast percentage of 39.6 × 10 3 /l and 45% respectively, compared to 4.2 × 10 3 /l and 12% for the excluded patients. This is presumed to reflect a tendency for larger numbers of cells to be submitted to the repository for patients who had a high WBC.
We attempted PCR analysis on 264 DNA specimens, ie 132 patients each matched with their control T cells which had been separated from the leukemic blasts by magnetic bead as well as flow cytometric sorting (see Methods). In 125 patients, DNA from both leukemic blasts and control T cells was successfully amplified. We then compared the lengths of the fluorescently labeled PCR products of three different microsatellite loci (BAT25, BAT26 and BAT 40) by automated capillary gel electrophoresis in order to detect expansions or contractions. The fluorescently labeled procedure coupled with the capillary electrophoresis and graphic quantitation made interpretation of the results straightforward.
MSI was detected in none of the successful 125 cases (see Figures 2 and 3) . The prevalence of MSI in secondary AML was 0/57 (0%). The Bonferroni-adjusted 95% upper confidence limit suggested that the true prevalence is unlikely to be higher than 7%. The prevalence of MSI in de novo AML was 0/46 (0%) with Bonferroni adjusted 95% confidence limit of 9%. Finally for relapsed or refractory AML, the prevalence of MSI was 0/22 (0%) with Bonferroni adjusted 95% confidence limit of 17%. The seven failures included five secondary and two de novo cases. These results are compared to the literature in Table 2 which summarizes various studies of MSI in acute myelogenous leukemia to date. Each study is somewhat different in its methodology, although all studies excluding this report have used gel radiometric methods. Results have ranged from a low of 0% in de novo AML to as high as 94% in t-AML. With relapsed and secondary AML reported with intermediate amounts of MSI.
To examine whether the presence of MSI might vary over time for individual patients, subsequent or prior specimens of marrow or blood were analyzed for 15 patients. These included 11 patients whose 9031 prestudy specimens were included in the analyses above, and for whom subsequent specimens were available (relapse specimens from six patients who achieved complete (CR), resistant disease specimens from four patients who failed to achieve CR, and one CR specimen). For the initial four patients, whose relapse or refractory disease specimens from studies 8326 or 9126 were included in the analyses above, prior specimens collected 
Figure 2
Example case of colon carcinoma displaying MSI at all three loci. The panels show the distribution of lengths of the three different fluorescently labeled PCR products from the BAT25, BAT26, and BAT40 microsatellite loci. Each set of primers has been labeled with a different fluorochrome (represented by different colors of lines) which has been incorporated into the PCR product. BAT25 products are represented by a blue line representing FAM fluorescence, BAT26 by the black line representing HEX fluorescence, and BAT40 by the green line representing TET fluorescence. An automated gel capillary electrophoresis instrument detects product lengths and prints a graph of the frequency of each length. The top frame shows the distribution of lengths of PCR products from DNA extracted from adjacent normal colon tissue adjacent to the tumor. This tissue was microdissected away from the carcinoma in order to serve as the control DNA. The bottom frame displays the PCR products from the cancerous portion of tissue showing clear shifts of the peaks to the left with all three colors (shortening of length of products) reflecting contraction at all three loci indicating that microsatellite instability is present. As can be seen, the fluorescently labeled procedure coupled with the capillary electrophoresis and graphic quantitation make interpretation of the results straight forward.
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Figure 3
Example case of AML not showing MSI. The top panel shows amplified DNA extracted from the normal control T cells which had been separated from the leukemic myeloblasts by magnetic bead and flow cytometric sorting. The bottom panel shows the distribution of PCR products from the patient's myeloblasts. As can be seen, there is no difference in the pattern of distribution of product lengths between the two specimens. This result clearly indicates that there has been no expansion or contraction at the microsatellite loci. before they started their initial frontline therapy for AML were available. MSI was not observed in any of these specimens.
Discussion
We have analyzed 132 patients with adult AML for MSI with an emphasis on elderly (Ͼ55 years), relapsed, and secondary (including therapy-induced) AML. We report no evidence of MSI (0%) in any of the 125 cases successfully studied. Using the Bonferroni adjustment, we estimated with an overall confidence level of at least 95% that the true rate of MSI in our cases could be as high as 9% in de novo AML, 7% in secondary AML, or 17% in relapsed/refractory AML. Our studies are therefore in essential agreement with many of the previously published works with smaller numbers of cases. In these previous studies, the analytical techniques have varied widely.
Controls have included either remission samples, separated normal T cells, bone marrow fibroblasts, or buccal smears. Different loci have been chosen for microsatellite analysis based on different criteria (randomly chosen, mono-, di-, trior tetranucleotide repeats, chosen for proximity to tumor suppresser genes, or proximity to breakpoint cluster regions). Different numbers of loci have been chosen (ranging from 3 to 69). Different detection methods used (radioisotope vs fluorescent). Different criteria for what constitutes MSI (shift in the length of one loci vs two or more loci) have been employed. Results have varied dramatically. The studies summarized in Table 2 highlight some of the complexities in comparing studies between different institutions in a burgeoning field without as yet standardized methodology. We carefully chose the BAT loci (BAT25, BAT26 and BAT40) for our primer sets because of their established track record in the literature and also because they have been parti-1049 cularly sensitive in our hands. Primers to these loci detected MSI in approximately 10% of 200 cases of colon cancer in our prior study (manuscript in progress). In that work, the positive cases were further tested against a panel of nine different loci (D8S254, NM23, D18S35, TP53, D5S346, D2S123, D1S2883, D3S1611, D7S501) and all showed MSI in the larger panel as well. Conversely, 70 cases negative for MSI using the BAT loci were also tested against the larger panel and remained negative, indicating a 100% agreement between screening with the three BAT loci and the complete 12 loci panel. In addition, BAT25 and BAT40 were used as part of an eight loci panel in a prior study of MSI in t-AML. The two BAT loci alone revealed MSI in all 15 of the cases considered MSI positive in that work. 21 These results demonstrated that the two BAT loci alone were as sensitive as their full eight loci panel. Finally, a recent study examining the usefulness of 31 different loci for their utility in detecting MSI in colon carcinoma recommended an initial panel of five loci (BAT26, BAT40, Mfd15, APC, D2S123) followed by five more loci if necessary (BAT25, D10S197, D18S58, D18S69, MYCL1). These recommended panels included all three of the mononucleotide repeat BAT loci. The other loci selected for the panel were all mononucleotide repeats like the BAT loci since these very short repeats demonstrated the highest mean detection frequency per marker. Importantly, BAT26 and BAT40 were distinguished as showing the clearest shifts in length and therefore the greatest ease of interpretation of all loci tested. These two loci were recommended along with other mononucleotide repeat loci as being the most sensitive for screening. 7 These studies and our own experience allow us to conclude that the three BAT loci are completely adequate for MSI screening.
In this study, the patients' own T cells were chosen as the normal, negative control as a comparison for the leukemic cells' DNA pattern. T cells were chosen for two reasons: (1) they are generally not involved in myelodysplastic syndromes or AML; and (2) they are readily available by separation techniques from the primary diagnostic bone marrow specimen. Several studies using clonality assays that take advantage of X-chromosome polymorphisms have examined the issue of whether T cells are involved in MDS syndromes. Most studies have shown that T lymphocytes are not part of the granulocytic/monocytic clone present in MDS, [25] [26] [27] however, a few studies have reported that T cells may be part of the clonal population. [28] [29] [30] Analysis of X-chromosome polymorphisms, though informative, may be flawed since skewed patterns of X-inactivation, mimicking clonal populations, have recently been reported in normal and elderly females using these techniques. 31, 32 T cells have previously been used successfully as controls in a study of MSI in B cell chronic lymphocytic leukemia. 11 Alternatively, 'remission' marrows could have been used as a negative control DNA source, however, the persistence of low levels of morphologically undetectable numbers of leukemia cells could have lead to false interpretation. The appropriateness of complete remission samples as controls depends on the adequacy of evaluation for minimal residual disease. Finally, our prior work with colon carcinoma has allowed us to recognize the appearance of typical expansions or contraction patterns in the BAT microsatellite loci using our automated method and none of these characteristic changes were seen by three of the co-authors (LR, JR, CW).
The automated fluorescent method for evaluation of MSI is helpful, speedy, and makes visual interpretation of the product lengths easy to assess as compared with the more common and time-consuming radioisotope procedures. Although both Leukemia the fluorescent and radioisotope procedures are plagued by slipped strand mispairing which creates shadow bands as pointed out by other authors, the fluorescent print out is much easier to interpret over the indistinct bands of the radioactive method. 33, 34 Fluorescent technology using this instrument has been used in prior work in colon carcinoma and was able to detect MSI when tumor DNA was contaminated by up to 50% normal DNA. 35 We performed an experiment diluting tumor with normal DNA and confirmed that in our hands, MSI could be detected at 50% dilution of tumor in normal DNA as well. Because of the purity of our samples due to the sequential enrichment and sorting steps, we are confident that the dilutional sensitivity of our assay was not a technical issue in our negative results.
The reports on MSI in acute myelogenous leukemia at this point have shown variable MSI from 0-94% (see Table 2 ). In three studies of de novo AML (62 cases), MSI appeared to be rare, 0%. 15, 18, 20 In unselected AML (82 cases), MSI was reported at low levels (3-10%), 10, 16, 17 as was otherwise unspecified AML at diagnosis in 17 patients (12%). 12 Relapsed AML was reported to have a range of 0% or 35% MSI in two studies with a total of 21 cases. 12, 15 Similarly, AML arising from MDS (0%, 20% or 67% in 26 total combined cases), 15, 18, 19 and myelodysplastic syndromes (0%, 11% or 33% in 22 combined cases) 15, 20, 36 have variable MSI. The highest reported rate of MSI was in t-AML (94% of 16 cases) in one report however, in another study MSI was found in only 1/14 cases or 7%. 20, 21 However, in the present study we found no MSI (0%) in any of our 125 patients successfully amplified despite the various clinical and cytogenetic groups studied. Given the variety of methodologies used in the various studies cited above, our results are probably not at variance with the reported results in de novo and randomly chosen AML. The findings in one each of the t-AML and post-MDS AML papers are more difficult to reconcile. 15, 21 Study design factors including low numbers of cases, pre-analytical bias in case selection, technical differences (number and location of loci), interpretive (such as computer graphs vs gels), criteria of number of loci showing expansion or contraction for calling a case MSI-positive, and differences in negative control tissues used may account for the differences. Possibly the findings of high MSI in t-AML previously reported were more related to widespread loss of heterozygosity at multiple loci including TP53 than true MSI. 21, [37] [38] [39] [40] [41] [42] In summary, we have conducted a retrospective survey of 132 patients with de novo, elderly, secondary, and relapsed AML for the presence of MSI and have found no evidence of this type of genetic instability in 125 cases. This finding suggests that DNA mismatch repair deficiency may not be a common factor in leukemogenesis. Future studies could include techniques to assess alternative mechanisms facilitating genomic damage including a search for deficiencies in other mechanisms of DNA repair (such as nucleotide excision repair) or alteration in methylation status of DNA repair genes. More specifically, chromosomal instability leading to abnormal chromosome number and aneuploidy has recently been associated with the loss of function of a mitotic checkpoint. 43 Since many of our AML cases are in fact associated with chromosomal loss and aneuploidy, this may be a fertile area for future investigation in these cases. Finally, other factors predisposing to DNA damage such as congenital or acquired factors affecting mutagen absorption, distribution, detoxification (ie polymorphisms in key detoxifying enzymes) or elimination should be explored.
